Searched for
ELI LILLY STOCK VALUATION
US stocks: Vedanta's CopperTech Metals targets $3.6 billion valuation in US IPOCopperTech Metals is targeting a valuation of $3.57 billion in its forthcoming U.S. IPO, aspiring to generate up to $423.5 million. This pr...- US Stocks | AI chip slump extends on Wall St as SanDisk sinks 12%, Micron drops 9% and AMD falls 5%Wall Street witnessed a significant downturn in semiconductor stocks Tuesday, impacting major AI beneficiaries. Memory chipmakers like SanD...
- Investors expecting 15-20% returns may be disappointed: Rajeev ThakkarInvestors should brace for lower nominal equity returns, as corporate profit growth moderates, according to PPFAS Mutual Fund's Rajeev Thak...
- India’s biggest equity fund makes contrarian bet on IT stocksIndia’s largest actively managed equity fund, PPFAS Flexi Cap, is increasing exposure to beaten-down IT stocks, taking a contrarian view on...
- US stocks: Oaktree-backed ITG targets $2.7 billion valuation in US IPODigital infrastructure firm ITG is aiming for a valuation of up to $2.67 billion in its US stock market debut, seeking to raise as much as ...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Infosys, HCL Tech, Coforge, other IT stocks rise up to 3% a day after a massive crash. What lies ahead?IT stocks rebounded after a sharp sell-off triggered by Accenture’s guidance cut, with gains led by Coforge and Tech Mahindra. Analysts see...
- SpaceX surges past Amazon, Microsoft: Why are Elon Musk-led company's stocks, valuation rising?SpaceX shares surged early on Tuesday as investors bet on Elon Musk's sprawling empire that spans rockets to AI, even though the stock carr...
- Trump's unusual stock frenzy: Portfolio shows 3,600 trades in 90 daysTrump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activ...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- India's Electronics Mart eyes new markets as tech hubs fear job lossesElectronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...
- CEA Anantha Nageswaran says AI stock valuations definitely in a bubbleIndia's Chief Economic Advisor V Anantha Nageswaran warns that artificial intelligence stock valuations are a bubble. He believes the narra...
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- US stocks: Musk's SpaceX prices record $75 billion IPO at $135 a shareSpaceX has priced its record-breaking U.S. IPO at $135 per share, raising $75 billion and valuing the company at $1.77 trillion. This makes...
- US stocks: S&P 500, Nasdaq end up as tech, chipmakers reboundU.S. stocks largely rose Monday, with the Nasdaq and chipmakers leading the gains as investors sought bargains after Friday's selloff. Reli...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
Load More
